Genentech reported that it will purchase Amphora's entire program for an unnamed early-stage oncology target with the potential to treat multiple oncology indications.
The company thus acquired all the intellectual property for the program, including the preclinical lead and several backup series.
“Amphora's drug discovery engine has produced and is continuing to produce extremely high quality new products,” points out C. Nicholas Hodge, Ph.D., Amphora's CSO and founder. “Amphora has shown that it is capable of moving programs quickly and cost-effectively from screening to proof-of-concept with surprisingly low attrition rates.”